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ABSTRACT Methionine adenosyltransferase (MAT)
is the enzyme that catalyzes the synthesis of S-adeno-
sylmethionine (AdoMet), the main donor of methyl
groups in the cell. In mammals MAT is the product of
two genes, MAT1A and MAT2A. MAT1A is expressed
only in the mature liver whereas fetal hepatocytes,
extrahepatic tissues and liver cancer cells express
MAT2A. The mechanisms behind the tissue and differ-
entiation state specific MAT1A expression are not
known. In the present work we examined MAT1A
promoter methylation status by means of methylation
sensitive restriction enzyme analysis. Our data indicate
that MAT1A promoter is hypomethylated in liver and
hypermethylated in kidney and fetal rat hepatocytes,
indicating that this modification is tissue specific and
developmentally regulated. Immunoprecipitation of
mononucleosomes from liver and kidney tissues with
antibodies mainly specific to acetylated histone H4 and
subsequent Southern blot analysis with a MAT1A pro-
moter probe demonstrated that MAT1A expression is
linked to elevated levels of chromatin acetylation. Early
changes in MAT1A methylation are already observed in
the precancerous cirrhotic livers from rats, which show
reduced MAT1A expression. Human hepatoma cell
lines in which MAT1A is not expressed were also
hypermethylated at this locus. Finally we demonstrate
that MAT1A expression is reactivated in the human
hepatoma cell line HepG2 treated with 5-aza-2*-deoxy-
cytidine or the histone deacetylase inhibitor trichosta-
tin, suggesting a role for DNA hypermethylation and
histone deacetylation in MAT1A silencing.—Torres, L.,
A´vila, M. A., Carretero, M. V., Latasa, M. U., Caballe-
rı´a, J., Lo´pez-Rodas, G., Boukaba, A., Lu, S. C., Franco,
L., Mato, J. M. Liver-specific methionine adenosyltrans-
ferase MAT1A gene expression is associated with a
specific pattern of promoter methylation and histone
acetylation: implications for MAT1A silencing during
transformation. FASEB J. 14, 95–102 (2000)
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Methionine adenosyltransferase (mat) is an es-
sential enzyme that catalyzes the formation of S-
adenosylmethionine (AdoMet), the most important
methyl donor in cellular metabolism (1, 2). MAT
activity in mammals is the product of two genes,
MAT1A and MAT2A, which display a tissue-specific
pattern of expression. MAT1A is expressed only in
the adult liver whereas MAT2A shows a wider distri-
bution, being responsible for AdoMet synthesis in
the extrahepatic tissues (reviewed in ref 2). In addi-
tion, MAT2A is expressed in the fetal liver, where it is
replaced by MAT1A upon maturation of this organ
(3). Similarly, in the transformed hepatocyte, a
switch in MAT gene expression is observed and the
dedifferentiated hepatoma cell mimics the fetal pat-
tern by expressing MAT2A in place of the liver-
specific MAT1A (4). This switch in MAT gene expres-
sion appears to confer a growth advantage to the
tumor cell (5).
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Although all this evidence clearly establishes that
MAT1A is a tissue-specific gene silenced outside the
liver and in situations such as development and
malignant transformation, the mechanisms behind
this tightly controlled pattern of expression are not
known. CpG methylation in mammalian DNA has
been linked for many years to the establishment of
tissue-specific patterns of gene expression (6, 7).
However, the molecular mechanisms underlying
methylation-dependent repression of gene expres-
sion have only recently been elucidated. The recruit-
ment of histone deacetylase, by means of methylated
DNA binding proteins such as MeCP2, seems to be
critical for assembly of the methylated sequences
into a condensed state (8, 9). This situation renders
the promoter regions inaccessible to the transcrip-
tion machinery and thus can block transcription
(10–12). In light of these recent developments, we
have searched for the molecular mechanisms that
may explain the tissue- and differentiation stage-
specific expression of MAT1A.
MATERIALS AND METHODS
General procedures
Fetal rat hepatocytes (gestational day 19) were prepared by
collagenase digestion of pooled fetal livers as reported previ-
ously (3). The human hepatoma cell line HepG2 was grown
in DMEM medium supplemented with 10% fetal calf serum,
glutamine, and antibiotics. Treatments were performed on
exponentially growing cultures. Total RNA from cells and
tissues was obtained by the guanidinium thiocyanate method.
Aliquots (20 mg) of total RNA were size fractioned by electro-
phoresis in agarose gels under denaturing conditions, blot-
ted, and fixed on Nytran (Schleicher and Schuell, Keene,
N.H.) membranes using standard procedures. Blots were
prehybridized and hybridized as described (13). Human and
rat MAT1A cDNAs probes (14, 15) were labeled with
[a-32P]dCTP (Amersham Pharmacia Biotech, Amersham,
U.K.) by random priming. Hybridization with a probe for 18S
rRNA was performed as loading control. Membranes were
then exposed to X-ray films. Genomic DNA was prepared as
described previously (16). Aliquots of high molecular weight
DNA (10 mg) were digested to completion with restriction
enzymes (Boehringer Mannheim, Mannheim, Germany),
loaded on agarose gels, electrophoresed, and blotted onto
Nytran membranes as described (17). Hybridizations were
carried out with a 1.4 kb SspI-SmaI probe derived from the rat
MAT1A promoter (probe 1) (18) or with the human MAT1A
full-length cDNA (15) labeled with [a-32P]dCTP. Membranes
were then exposed to X-ray films.
Induction of cirrhosis
Male Wistar rats (250 g) were fed ad libitum a standard
laboratory diet and received humane care according to our
institution’s guidelines for the use of laboratory animals in
research. Cirrhosis was induced by intraperitoneal injections
of CCl4 (0.5 ml administered twice a week) as described
previously (19). The establishment of cirrhosis was monitored
by histological examination of liver sections from treated
animals (19). Rats were killed after 9 wk of treatment by
cardiac puncture and exsanguination.
Nuclei isolation
Liver and kidney from Wistar rats were placed in buffer A
(0.25M sucrose, 10 mM NaCl, 5 mM MgCl2, 2 mM EDTA,
0.2% Triton X-100, 2 mM p-aminobenzamidine, 1 mM PMSF,
2.5 mg/ml leupeptin, 1.5 mg/ml chymostatin, 50 mM Tris-
HCl, pH 7.5) at a ratio of 5 ml buffer per gram of tissue. All
the steps were carried out at 4°C. Tissues were homogenized
on ice; after filtration of the homogenates through 200 and
100 mM nylon filters, nuclei were collected by centrifugation
at 1500 3 g for 5 min and the sediment was washed twice in
buffer B (buffer A without Triton and EDTA). Nuclear pellets
were resuspended in the same buffer and placed on a
discontinuous sucrose gradient (0.75 M/1.75 M) in buffer B.
After centrifugation at 10,000 3 g for 30 min, nuclei were
collected from the 1.75 M sucrose cushion and washed twice
with buffer B.
Micrococcal nuclease digestion
Nuclei were resuspended in digestion buffer (0.25 M sucrose,
10 mM NaCl, 3 mM MgCl2, 1 mM CaCl2, 10 mM sodium
butyrate, 2 mM p-aminobenzamidine, 1 mM PMSF, 2.5 mg/ml
leupeptin, 1.5 mg/ml chymostatin, 50 mM Tris-HCl, pH 7.5)
at a concentration of 5 mg DNA/milliliter. Nuclei from liver
were digested with micrococcal nuclease (Worthington, Free-
hold, N.J.) at 15 u per mg DNA and nuclei from kidney with
20 u per mg DNA for 10 min at 37°C. The digestion was
stopped by adding EDTA to a final concentration of 5 mM
and the samples were cooled on ice and centrifuged at
12,000 3 g for 10 min. The supernatant was saved and the
pellet was resuspended in lysis buffer (0.25 mM EDTA, 10 mM
sodium butyrate, 2 mM p-aminobenzamidine, 1 mM PMSF,
2.5 mg/ml leupeptin, 1.5 mg/ml chymostatin, 50 mM Tris-
HCl, pH 7.5) incubated 10 min on ice and recentrifuged as
above. The first and second supernatants were pooled and
analyzed on agarose gels to determine the extent of the
micrococcal digestion.
Production of antisera to hyperacetylated histone H4 and
antibody purification
Polyclonal antisera to hyperacetylated H4 were raised by
immunization with a synthetic peptide corresponding to
residues 2–19 of histone H4 and acetylated in the ε-amino
groups of lysines 5, 8, 12, and 16. The acetylated peptide was
custom-synthesized by Genosys and coupled to keyhole limpet
hemocyanin (20). The immunoglobulin (IgG) fraction was
purified by HiTrap protein-A FPLC chromatography accord-
ing to the manufacturer (Amersham Pharmacia Biotech).
Immunofractionation of nucleosomes
Immunofractionation of nucleosomes obtained by micrococ-
cal nuclease digestion of nuclei were performed essentially as
described previously (21). FPLC-purified antibody (500 mg of
IgG) dissolved in fractionation buffer (50 mM NaCl, 10 mM
sodium butyrate, 1 mM EDTA, 0.2 mM p-aminobenzamidine,
0.1 mM PMSF, 2.5 mg/ml leupeptin, 1.5 mg/ml chymostatin,
10 mM Tris-HCl, pH 7.5) was incubated with 100 mg of
protein A Sepharose prewashed with fractionation buffer for
3 h at 4°C under gentle rotation. The protein A Sepharose-
bound antibody was mixed with 2 mg of soluble chromatin in
a final volume of 3 ml of fractionation buffer and incubated
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overnight with gentle rotation at 4°C. The immunocomplexes
were collected by centrifugation (6500 3 g, 1 min) on a 0.65
mM Ultrafree filter unit (Millipore) and the filtered through
fraction was removed and stored on ice. Protein A Sepharose
beads were washed eight times with 500 ml of fractionation
buffer as before and filtrates were pooled together (unbound
fraction). Antibody-bound fraction was eluted from protein A
Sepharose by addition of 400 ml of 1.5% sodium dodecyl
sulfate (SDS) in fractionation buffer and rotated for 15 min at
room temperature. After centrifugation as before, the eluate
was saved and protein A Sepharose was reincubated for
another 15 min period with 400 ml of 0.5% SDS in fraction-
ation buffer. The two eluates (bound fraction) were pooled.
DNA from all chromatin fractions (input, unbound, and
bound) was purified and quantitated by fluorescence with
PicoGreen dye (Molecular Probes, Eugene, Oreg.).
Slot-blot and hybridization analysis
DNA samples were denatured in 0.5 M NaOH, 1.5 M NaCl for
10 min at 37°C, followed by 1 min at 95°C and then kept on
ice. 150 ng of DNA from each fraction were loaded through
a slot-blot manifold (Bio-Rad, Hercules, Calif.) on a Biodyne
B membrane (Pall) prewetted in 23 SSC. The filters were
immersed in denaturation solution for 5 min, neutralized in
1.5 M NaCl, 1 mM EDTA, 0.5 M Tris-HCl, pH 7.5 for 30 s and
the membranes were dried by baking at 80°C for 30 min.
Hybridizations were carried out using a 750 bp MspI-SmaI
probe derived from MAT1A promoter (probe 2). The probe
was labeled by random priming. Filters were prehybridized
for 2 h and hybridized overnight using Quick Hyb solution
(Stratagene, San Diego, Calif.) at 65°C in the presence of 200
mg of heat-denatured salmon sperm DNA. Filters were rinsed
in 23 SSC, 0.1% SDS and washed sequentially twice with 23
SSC, 0.1% SDS at 65°C for 5 min, once with 23 SSC, 0.1%
SDS at 65°C for 30 min, and once with 0.23 SSC, 0.1% SDS
at 65°C for 20 min. The radioactivity present in the filters was
initially measured with an InstantImager (Packard, Downers
Grove, Ill.) and the filters were then autoradiographed.
RESULTS
As mentioned, MAT1A is expressed only in liver but
is silenced in all other tissues. We first evaluated
whether this pattern of expression correlated with
the methylation status of MAT1A promoter in liver
and extrahepatic tissues such as the kidney. For this
purpose, we used the methylation-sensitive restric-
tion isoschizomers MspI and HpaII. Both enzymes
recognize the sequence CCGG, but HpaII cannot
cleave if the internal C is methylated whereas meth-
ylation at the external C is inhibitory for both
enzymes (22). Two MspI/HpaII restriction sites are
present in the reported 59-flanking region of rat
MAT1A (18) (Fig. 1A). Genomic DNA samples from
rat liver and kidney were sequentially digested with
the methylation-insensitive enzyme SspI and either
MspI or HpaII. Southern blot analysis was then
carried out using a 1.4 kb SspI-SmaI probe from rat
MAT1A promoter (probe 1 in Fig. 1A). DNA from
liver was unmethylated as indicated by the presence
of two fragments of 0.64 and 0.75 kb, respectively,
consistent with cleavage at the MspI/HpaII sites by
both enzymes (Fig. 1B). In the case of kidney DNA,
MspI treatment resulted in the same pattern ob-
tained in liver, but HpaII could not cleave with the
same efficiency observed in hepatic tissue and gen-
erated higher molecular weight bands (Fig. 1B).
These results are consistent with hypomethylation of
the cytosines located at positions 213 and 2755 of
MAT1A promoter in liver and enhanced levels of
methylation of these two sites in kidney DNA. Other
tissues examined, such as spleen and heart, gener-
ated the same restriction pattern observed in the
kidney (data not shown).
The mechanism of gene silencing by means of
cytosine methylation has been recently worked out
through the implication of histone deacetylation (8,
9). We wanted to ascertain the degree of acetylation
displayed in vivo by the histones associated with
MAT1A promoter in the liver and kidney and
whether this covalent modification correlated with
the degree of promoter methylation. Mononucleo-
somes obtained from both tissues were immunopre-
cipitated with an antibody mainly specific to acety-
lated histone H4, as described in Materials and
Methods. DNA was extracted from the input, un-
bound, and bound fractions; equal amounts from
each fraction were immobilized onto nylon mem-
branes by slot-blot and hybridized with a 750 bp
probe derived from the 59-flanking region of rat liver
MAT1A gene, close to the transcription initiation site
(probe 2 in Fig. 1A). The intensity of signal from the
antibody-bound slot relative to the intensity from the
input slot gives the enrichment generated by the
antibody selection. Our data show a strong enrich-
ment (10- to 15-fold) in the bound fraction com-
pared to the input fraction in liver, where the gene is
actively transcribed. However, no preferential selec-
tion by the antibody was observed in the kidney,
indicating the absence of hyperacetylation in this
region of MAT1A in a tissue where the gene is not
expressed.
We have also analyzed MAT1A promoter methyl-
ation in developing rat hepatocytes. Genomic DNA
was isolated from fetal rat hepatocytes correspond-
ing to gestational day 19, when MAT1A expression is
negligible (Fig. 2) (3), and then digested with SspI
and MspI or HpaII. The restriction pattern obtained
with probe 1 indicated that in the developing hepa-
tocyte the MAT1A promoter is hypermethylated, as
evidenced by the appearance of high molecular
weight bands in the HpaII-treated samples (Fig. 2).
This pattern was identical to that obtained in extra-
hepatic tissues, where MAT1A is not expressed.
A significant number of cirrhotic patients develop
hepatocellular carcinoma, thus, the cirrhotic liver
could be considered to be in a precancerous condi-
tion (23, 24). This notion along with our previous
observation of MAT1A silencing in transformed liver
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(4) led us to evaluate MAT1A expression in a rat
model of CCl4-induced cirrhosis. In agreement with
our previous results (19), no large changes were
observed in MAT1A mRNA levels, although a signif-
icant trend toward a reduction in the hepatic con-
tent of this messenger was observed (Fig. 3A).
MAT1A promoter methylation was evaluated in con-
trol and cirrhotic livers using the same strategy
described above. High molecular weight bands were
detected in the HpaII-digested samples from cir-
rhotic rat liver, which is consistent with enhanced
methylation of the MspI/HpaII sites in MAT1A pro-
moter (Fig. 3B).
As mentioned before, transformed hepatic cells
lose MAT1A expression (4). We have tested whether
the silencing of MAT1A in this condition is accom-
panied by changes in MAT1A methylation. Since the
human MAT1A promoter has not been cloned, we
performed MspI/HpaII restriction analysis using a
full-length human MAT1A cDNA clone as a probe
(15). As observed in Fig. 3A, HpaII treatment of
normal human liver yielded low molecular weight
bands that were absent in the transformed hepatic
cells. This result indicates hypermethylation at the
internal C of CCGG sites of MAT1A in HepG2 cells.
Similar results consistent with hypermethylation of
MAT1A were obtained in Hep3B cells, another hu-
man hepatoma cell line in which MAT1A is also
silenced (data not shown). To test whether this
epigenetic modification could play a role in MAT1A
silencing, we tried to modify the methylation status
of this cell line by treatment with the demethylating
agent 5-aza-29-deoxycytidine (5-Aza-CdR) (25). For
this purpose, HepG2 cells were incubated with 0.1
mM 5-Aza-CdR for 24 or 48 h and MAT1A expression
was assessed by Northern blotting. Under these
conditions, MAT1A expression was induced after
48 h of treatment (Fig. 4B). It has recently been
established that methylation-dependent gene silenc-
ing involves histone deacetylation (8, 9). These ob-
servations led us to evaluate the effect of the histone
deacetylase inhibitor trichostatin A (26) on MAT1A
expression in HepG2 cells. In this case, 24 h of
treatment with 3 mM trichostatin A was sufficient to
induce MAT1A mRNA as detected by Northern
blotting (Fig. 4B).
Figure 1. Analysis of the methylation and histone acetylation status of the 59 region of MAT1A gene in rat liver and kidney. A)
Restriction map of MAT1A promoter indicating the location of MspI/HpaII restriction sites and the probes used in the
experiments represented here and in subsequent figures. Probe 1 is a 1.4 kb SspI-MspI fragment and probe 2 is a 0.75 kb
MspI-SmaI fragment, both derived from rat MAT1A promoter. B) Southern blot analysis of rat liver and kidney genomic DNA
after digestion with SspI and MspI (M) or HpaII (H), performed with probe 1 derived from MAT1A promoter. The migration
of molecular weight markers is indicated (MWM). Lower panel shows the levels of MAT1A expression in liver and kidney as
assayed by Northern blotting with a rat cDNA probe. Ethidium bromide staining of the gel is shown as loading control. C)
Mononucleosomes from liver and kidney were prepared and immunoprecipitated with antibodies specific mainly to acetylated
histone H4, as described in Materials and Methods. DNA was extracted from input, unbound, and bound fractions; equal
amounts were loaded and analyzed by slot-blot hybridization with probe 2 from MAT1A promoter. Quantitation of the
radioactivity incorporated in each slot is also shown. Representative autoradiograms are shown.
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DISCUSSION
Mammalian liver plays a central role in the metabo-
lism of methionine (27). This function is met in part
by the presence of a liver-specific MAT enzyme,
which is the product of the MAT1A gene expressed
only in this organ (2). We have recently reported the
cloning and functional analysis of rat liver MAT1A
promoter (18). We observed that this promoter was
able to drive the expression of a reporter gene not
only in liver-type cells such as HepG2, but also in the
nonhepatic cell line CHO (18). These observations
raised the possibility that the silencing of MAT1A
outside the liver could be the consequence of situa-
tions known to repress transcription, such as DNA
methylation and chromatin compaction (7, 25),
rather than to the lack of liver-specific transcription
factors.
In the present work we have first demonstrated
that MAT1A promoter methylation is tissue specific,
being hypomethylated in liver but hypermethylated
in nonexpressing tissues such as the kidney. We have
observed that MAT1A promoter is also hypermethy-
lated in the developing hepatocyte, in which we had
previously demonstrated that this gene is not ex-
pressed and MAT activity derives from the expres-
sion of the extrahepatic MAT2A gene (3). Thus,
cytosine methylation in the 59 region of MAT1A
conforms to a pattern of hypermethylation, where
the gene is inactive, and hypomethylation, where the
gene is active. DNA methylation has been generally
associated to an inactive chromatin conformation;
however, the mechanisms behind the transcriptional
repression dictated by methyl groups in the 5-posi-
tion of cytosine residues had not been exposed until
recently. The recruitment of histone deacetylases to
methylated 59CpG dinucleotides through methylcy-
tosine binding proteins such as MeCP2 can lead to a
condensed and inactive chromatin (8, 9). These
observations linking DNA methylation to histone
deacetylation led us to evaluate the degree of acety-
lation of histones associated with MAT1A promoter.
Immunoprecipitation of mononucleosomes with an-
tibodies specific to acetylated histone H4 indicated
Figure 3. Expression and methylation status of MAT1A pro-
moter in liver from control and CCl4-treated cirrhotic rats. A)
Levels of MAT1A mRNA in liver of control and cirrhotic rats
as assayed by Northern blotting. Data are the average of four
animals per group. Signal was normalized to 18S ribosomal
RNA in each lane. Differences between control and cirrhotic
groups were statistically significant (P,0.05). Representative
blots are shown. B) Genomic DNA samples from livers of
control and cirrhotic animals were digested with SspI and
MspI (M) or HpaII (H) and analyzed by Southern blotting
using probe 1 corresponding to MAT1A promoter as de-
scribed in Fig. 1. A representative blot is shown.
Figure 2. Methylation status of MAT1A promoter in adult and
fetal rat hepatocytes. Genomic DNA was extracted from adult
liver and fetal hepatocytes isolated from embryonic liver
(corresponding to gestational day 19). DNA samples were
digested with SspI and either MspI (M) or HpaII (H) and
subsequently analyzed by Southern blotting using probe 1
described in Fig. 1. The migration of molecular weight
markers (MWM) is indicated. Lower panel shows the expres-
sion of MAT1A in adult rat liver and fetal hepatocytes
obtained from gestational day 19 embryos as analyzed by
Northern blotting with a rat MAT1A cDNA probe. Ethidium
bromide staining of the gel is shown as loading control.
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that in liver MAT1A is enriched in the highly acety-
lated mononucleosome fraction, whereas in the kid-
ney MAT1A is not preferentially associated with
acetylated histones. The histone acetylation pattern
of MAT1A promoter in liver corresponds to that of
an actively transcribing gene; however, in the kidney
this pattern is that of a silent gene. Similar patterns
of histone acetylation have been reported for active
and silent genes, respectively (28). MAT1A promoter
methylation profile correlates with the local acetyla-
tion status of histones. Thus, in liver, where MAT1A
promoter is hypomethylated, elevated levels of his-
tone acetylation would result in a chromatin struc-
ture accessible to transcription factors whereas in the
kidney we find the opposite situation, which may be
consistent with a condensed and inactive chromatin
state (8, 9, 29). These observations may be relevant
to the mechanisms by which tissue-specific MAT1A
expression is achieved in vivo.
Hepatic methionine metabolism is altered in vari-
ous chronic liver disorders as well as in the trans-
formed liver (2, 30). We wanted to know whether the
MAT1A methylation pattern would be preserved in
situations of hepatocellular damage or abnormal
proliferation. We first examined the methylation
status of MAT1A in an experimental model of liver
cirrhosis, trying to reproduce a pathological condi-
tion that in many cases precedes the neoplastic
conversion of the liver (23, 24). Our data indicate
that enhanced levels of MAT1A promoter methyl-
ation can be detected in the liver of cirrhotic rats.
Although no marked changes in liver MAT1A expres-
sion occur in this model, a significant reduction
(30% compared to controls) in steady-state MAT1A
mRNA levels was detected. Although global DNA
hypomethylation has been observed in this model of
cirrhosis (31), it is known that DNA methyltrans-
ferase expression is higher in liver tissues that show
chronic hepatitis or cirrhosis (32). In this regard, de
novo methylation and reduced gene expression in
cirrhosis have been reported for certain loci such as
the D17S5 locus, in which the candidate tumor
suppressor HIC-1 was identified (33). Our present
findings indicate that MAT1A expression in diseased
liver is compromised and that hypermethylation of
its promoter region could participate in this process.
As we previously mentioned, MAT1A expression is
lost upon neoplastic transformation of the hepato-
cyte (4). MAT1A silencing is accompanied by the
induction of MAT2A, a situation that reproduces the
pattern of expression found in the fetal hepatocyte
(3). In addition, MAT2A is also induced under
conditions of active proliferation in the liver paren-
chyma as happens during liver regeneration after
partial hepatectomy (34). Thus, it appears that pro-
liferating cells may find an advantage in switching
MAT genes (5) whose products behave differently
from a kinetic and regulatory point of view (2).
Although global hypomethylation is a characteristic
of many transformed cells, certain genomic se-
quences such as that of tumor suppressor and tissue-
specific genes appear to be hypermethylated and
repressed in cancer (7). We next tested MAT1A
methylation status in the human transformed he-
patic cell line HepG2, in which MAT1A is silenced.
Our data indicate that hypermethylation of MAT1A
gene accompanies loss of expression. This cellular
model has allowed us to directly assess the role of
cytosine methylation and histone acetylation on
MAT1A expression regulation. We therefore treated
HepG2 cells with 5-Aza-CdR, a demethylating agent
well known for its ability to reactivate the expression
Figure 4. A) Methylation status of MAT1A locus in healthy
human liver and the human hepatoma cell line HepG2.
Genomic DNA extracted from control human liver and the
human transformed cell line HepG2 was digested with MspI
(M) or HpaII (H) and analyzed by Southern blotting using a
full-length human MAT1A cDNA as a probe. Asterisks indi-
cate bands present in HpaII-digested DNA from control
human liver that are absent in the HpaII-digested DNA from
HepG2 cells, indicating hypermethylation of CCGG sites.
Lower panel shows MAT1A expression in control human liver
and HepG2 cells as assayed by Northern blotting with the
same probe. Ethidium bromide staining of the gel is shown as
loading control. B) Effects of 5-Aza-CdR or trichostatin A on
MAT1A expression in HepG2 cells. Upper panel shows the
effect of 5-Aza-CdR treatment (0.1 mM) for 24 or 48 h on
MAT1A expression as analyzed by Northern blotting. Lower
panel shows the effect of 3 mM trichostatin A on MAT1A
mRNA levels after 24 h of treatment. Hybridization with a
probe specific for 18S ribosomal RNA was carried out as
loading control. Representative blots are shown.
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of genes silenced by de novo methylation (7, 35). In
the presence of 5-Aza-CdR, MAT1A expression was
induced after 48 h of treatment; this observation
suggests that methylation may indeed play a role in
the transcriptional regulation of this gene. A slower
rate of cell growth accompanied 5-Aza-CdR-medi-
ated induction of MAT1A expression (data not
shown). Growth arrest of tumor cells has previously
been observed in response to 5-Aza-CdR, and the
reactivation of genes such as the cell cycle regulatory
p16 gene, among others, may explain the effect of
this drug (35). However, it is worth mentioning that
when MAT1A is transfected into HepG2 cells, slower
rates of cell growth and DNA synthesis are observed
(5). As mentioned above, recent findings have dem-
onstrated that transcriptional repression associated
with cytosine methylation relies to a significant ex-
tent on histone deacetylation (8, 9). These observa-
tions prompted us to test whether this mechanism
could also participate in the silencing of MAT1A in
the transformed HepG2 cells. Our findings indicate
that treatment with the histone deacetylase inhibitor
trichostatin A (26) for 24 h restored MAT1A expres-
sion in HepG2 cells. Taken together, these observa-
tions suggest that MAT1A silencing during transfor-
mation is mediated by de novo cytosine methylation
and the recruitment of histone deacetylase, a situa-
tion in which a condensed and inactive chromatin
state is favored. These results also support a role for
MAT1A promoter methylation and histone acetyla-
tion in the maintenance of a tissue-specific expres-
sion profile, which may be progressively lost as the
transition from a healthy to a diseased and, finally,
neoplasic liver proceeds.
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